Objective To investigate the efficacy of different progestin-primed ovarian stimulation in non-polycystic ovarian morphology(non-PCOM) patients with high ovarian response. Methods A total of 711 cycles for in-vitro fertilization treatment(including 389 embryos transfer cycles) in our hospital from October 2018 to November 2019 were summarized in this retrospective study. All the patients were divided into three groups. In group A, 414 cycles for follicular phase gonadotropin-releasing hormone(GnRH) agonist long protocol(including 232 embryos transfer cycles)was used. In group B, 221 cycles for luteal phase GnRH agonist long protocol(including 121 embryos transfer cycles)was used. In group C, 76 cycles for GnRH antagonist protocol(including 36 embryos transfer cycles)was used. Results Follicular output rate(FORT) in group A was the highest. The number of oocytes, 2PN embryos and follicle-to-oocyte index in group B were the highest among the three groups,while the clinical pregnancy rate and implantation rate were the lowest. Luteinizing hormone on human chorionic gonadotropin injection day、estradiol level per follicle in group C were the highest,while FORT and the number of ≥16 mm dominant follicles were the lowest. Conclusion In non-PCOM patients with high ovarian response,follicular phase GnRH agonist protocol had better pregnancy outcome compared with luteal phase GnRH agonist protocol, and the GnRH antagonist protocol appeared to be more economical and safe.